Bristol-Myers
Squibb Company (NYSE:BMY) announced today that it has agreed to sell
$2.0 billion of senior unsecured notes: $750 million in aggregate
principal amount of 0.875% notes due 2017, $750 million in aggregate
principal amount of 2.000% notes due 2022 and $500 million in aggregate
principal amount of 3.250% notes due 2042 in an underwritten public
offering.
Citigroup Global Markets Inc., Barclays Capital Inc., Deutsche Bank
Securities Inc., J.P. Morgan Securities LLC, Merrill Lynch Pierce Fenner
& Smith Incorporated and Wells Fargo Securities, LLC are acting as joint
book-running managers of the underwriters.
Bristol-Myers Squibb intends to use the net proceeds from the offering,
the issuance of commercial paper and cash on hand to finance the
acquisition of Amylin Pharmaceuticals, Inc., pay costs and expenses
pursuant to the assumption agreements, to pay fee and expenses and/or
for general corporate purposes. The offering is expected to close on
July 31, 2012, subject to customary closing conditions.
When available, the final prospectus supplement and accompanying
prospectus relating to the offering of the notes may be obtained by
contacting one of the following joint book-running managers:
-
Citigroup Global Markets Inc., at: 877-858-5407
-
Barclays Capital Inc., at: 888-603-5847
-
Deutsche Bank Securities Inc., at: 800-503-4611
-
J.P. Morgan Securities LLC, at: 212-834-4533
-
Merrill Lynch, Pierce, Fenner & Smith Incorporated, at: 800-294-1322
-
Wells Fargo Securities, LLC, at: 800-326-5897
The final prospectus supplement and accompanying prospectus, when
available, may also be accessed through the SEC’s website at www.sec.gov.
These securities are offered pursuant to a registration statement that
has become effective under the Securities Act of 1933, as amended. These
securities are only offered by means of the prospectus supplement and
prospectus relating to the offering. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy, nor
shall there be any offer or sale of these securities in any state or
other jurisdiction, where the offer, solicitation or sale of these
securities would be unlawful prior to the registration or qualification
under the securities laws of any such state or other jurisdiction.
Forward-Looking Statements
This press release contains "forward-looking statements" as that term
is defined in the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are based on current expectations and involve
inherent risks and uncertainties, including factors that could delay,
divert or change any of them, and could cause actual outcomes and
results to differ materially from current expectations. No
forward-looking statement can be guaranteed. Forward-looking statements
in this press release should be evaluated together with the many risks
and uncertainties that affect Bristol-Myers Squibb's business, including
those identified in Bristol-Myers Squibb's Annual Report on Form 10-K
for the year ended December 31, 2011, particularly under "Item 1A. Risk
Factors". Bristol- Myers Squibb undertakes no obligation to
publicly update any forward-looking statement, whether as a result of
new information, future events or otherwise.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information, please
visit http://www.bms.com
or follow us on Twitter at http://twitter.com/bmsnews.
